InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Smilin_B Free
04/12/24 2:27 PM
profile icon
ErnieBilco PremiumMember
04/09/24 7:34 PM
profile icon
malata Free
04/09/24 10:47 AM
profile icon
ErnieBilco PremiumMember
04/04/24 2:52 PM
profile icon
malata Free
04/04/24 2:36 PM
profile icon
TrendTrade2016 Free
04/04/24 9:30 AM
profile icon
TrendTrade2016 Free
04/04/24 8:10 AM
profile icon
gail PremiumMember
04/04/24 12:40 AM
profile icon
TrendTrade2016 Free
04/04/24 12:12 AM
profile icon
TrendTrade2016 Free
04/03/24 1:10 PM
profile icon
TrendTrade2016 Free
04/02/24 11:14 AM
profile icon
TrendTrade2016 Free
04/02/24 11:03 AM
profile icon
oak4life20 Free
04/01/24 3:00 PM
profile icon
ErnieBilco PremiumMember
04/01/24 2:55 PM
Bullish
Bullish
profile icon
ErnieBilco PremiumMember
03/26/24 8:45 PM
profile icon
ErnieBilco PremiumMember
03/22/24 10:07 AM
Bullish
Bullish
profile icon
ErnieBilco PremiumMember
03/21/24 9:06 PM
profile icon
ErnieBilco PremiumMember
03/21/24 5:52 PM
profile icon
ErnieBilco PremiumMember
03/21/24 5:52 PM
profile icon
ErnieBilco PremiumMember
03/21/24 5:51 PM
profile icon
ErnieBilco PremiumMember
03/21/24 5:51 PM
profile icon
Smilin_B Free
05/27/22 6:32 PM
profile icon
Porterhouse10 Free
03/24/22 5:57 PM
profile icon
Pennyes Free
03/24/22 5:44 PM
profile icon
Porterhouse10 Free
03/24/22 5:33 PM
profile icon
Pennyes Free
03/22/22 8:05 PM
profile icon
Pennyes Free
03/22/22 3:37 PM
profile icon
Smilin_B Free
03/22/22 3:20 PM
profile icon
Pennyes Free
03/22/22 2:00 PM
profile icon
Smilin_B Free
03/22/22 1:55 PM
profile icon
Pennyes Free
03/22/22 1:53 PM
profile icon
Smilin_B Free
03/22/22 12:58 AM
profile icon
Pennyes Free
03/21/22 7:17 PM
profile icon
Pennyes Free
03/21/22 7:16 PM
profile icon
Pennyes Free
03/21/22 7:16 PM
profile icon
Pennyes Free
03/21/22 7:14 PM
profile icon
Smilin_B Free
12/15/21 1:00 AM
profile icon
Smilin_B Free
11/03/21 5:14 PM
profile icon
Biggeoff Free
11/02/21 2:26 PM
profile icon
Troytex Free
07/27/21 9:56 PM
profile icon
geocam PremiumMember
07/27/21 12:52 PM
profile icon
Troytex Free
07/26/21 9:39 PM
profile icon
geocam PremiumMember
07/24/21 2:25 PM
profile icon
Troytex Free
07/23/21 2:42 PM
profile icon
shimanoman Free
07/23/21 11:17 AM
profile icon
shimanoman Free
07/23/21 11:17 AM
profile icon
JJ8 Free
07/23/21 10:33 AM
profile icon
Troytex Free
07/23/21 10:02 AM

IGC Pharma, Inc. (IGC) RSS Feed

Followers
185
Posters
718
Posts (Today)
0
Posts (Total)
9219
Created
07/17/09
Type
Free
Moderators ErnieBilco

Patent Granted To IGC Pharma For Groundbreaking Drug Formulation To Treat Agitation In Alzheimer’s

  • December 19, 2023
 
 
 
 

– IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024 –

POTOMAC, MD., December 19, 2023 / IGC Pharma, Inc. (“IGC Pharma” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, announced today that Divisional Direction of Patents, Mexico, has issued a Granting Office Action (GOA) for its treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” The Company is optimistic that the success witnessed in Mexico can pave the way for additional approvals in the U.S. and Europe.

IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS). IGC-AD1, the Company’s lead therapeutic candidate, is a partial CB1 receptor agonist designed with anti-neuroinflammatory properties to address the underlying neurodegeneration resulting in neuropsychiatric symptoms. IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico. Today’s announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization.

Alzheimer’s disease is a global public health issue affecting an increasing number of individuals as the population ages. According to the Alzheimer’s Association, by 2050, nearly 13 million Americans will be grappling with Alzheimer’s, and related costs are projected to soar to $1 trillion. The burden extends beyond the individual to families, caregivers, and society at large, with approximately 76% of Alzheimer’s patients experiencing neuropsychiatric symptoms such as agitation.

IGC-AD1 is designed to potentially revolutionize the treatment of Alzheimer’s by improving the quality of life of millions of individuals affected by this devastating disease. The current Phase 2 trial, alongside future investigations, aims to validate the effectiveness of IGC-AD1 in managing agitation in Alzheimer’s and relieving caregiver burden.

IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer’s disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which are currently in different stages of clinical trials and development.

About IGC Pharma Inc. (dba IGC):

IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. IGC Pharma’s portfolio comprises of five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is a CB1r partial agonist currently in a Phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of Generative AI development, with projects including clinical trials, early detection of Alzheimer’s, and drug interactions with cannabinoids.

I
 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post